# US 2010/0167981 A1 · Encapsidation of Heterologous Entities into Virus-Like Particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167981 A1
- Document ID: US20100167981A1
- Status: Published application
- Kind: A1
- Application number: 12/621,416
- Filed: 2009-11-18
- Published: 2010-07-01
- Earliest claimed: 2008-11-18
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Bradley C. Bundy; James R. Swartz; Wei Chan
- Web page: https://patentgrep.com/patent/US20100167981A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12N 2795/10123: Virus like particles [VLP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Methods are provided for the utilization of bacterial cell-free extracts in the synthesis of high yields of virus like particles with encapsidated cargo.

## Claims

### Claim 1

A method for synthesis of virus like particles comprising encapsidated cargo in a cell-free in vitro reaction, the method comprising:
synthesizing virus coat proteins in a prokaryotic cell-free in vitro translation reaction in the presence of heterologous cargo;
wherein the virus coat proteins self-assemble into a stable virus like particle comprising at least 60 separate proteins; which VLP is free of a viral genome and comprises encapsidated heterologous cargo.

### Claim 2 (depends on 1)

The method of claim 1, wherein said virus coat protein is a bacteriophage coat protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein said bacteriophage is MS2.

### Claim 4 (depends on 1)

The method of claim 1, wherein said heterologous cargo is a molecular entity comprising a viral pac sequences.

### Claim 5 (depends on 2)

The method of claim 2, wherein said heterologous cargo is a molecular entity comprising an MS2 pac sequences.

### Claim 6 (depends on 5)

The method of claim 5, wherein said pac sequence is ACAUGAGGAUUACCCAUGU (SEQ ID NO:3).

### Claim 7 (depends on 4)

The method of claim 4, wherein said cargo is a nucleic acid.

### Claim 8 (depends on 7)

The method of claim 7, wherein said nucleic acid comprises a coding sequence.

### Claim 9 (depends on 7)

The method of claim 7, wherein said cargo comprises an anti-sense sequence.

### Claim 10 (depends on 7)

The method of claim 7, wherein said cargo is an siRNA.

### Claim 11 (depends on 7)

The method of claim 7, wherein said cargo is a microRNA.

### Claim 12 (depends on 4)

The method of claim 4, wherein said cargo is a polypeptide.

### Claim 13 (depends on 4)

The method of claim 4, wherein said cargo is a polysaccharide.

### Claim 14 (depends on 4)

The method of claim 4, wherein said cargo is a drug.

### Claim 15 (depends on 1)

A VLP produced according to the method set forth in claim 1.

### Claim 16 (depends on 1)

A kit for use in any of methods according to claim 1.

### Claim 17 (depends on 1)

The method of claim 1, wherein said prokaryotic cell-free in vitro translation reaction comprises exogenous translation initiation factors.

### Claim 18 (depends on 17)

The method of claim 17, wherein said exogenous translation initiation factors are infA, infB and infC, each at a concentration of at least about 1 μM.

### Claim 19 (depends on 18)

The method of claim 18, wherein said prokaryotic cell-free in vitro translation reaction comprises plasmid DNA at a concentration of not more that about 2.5 nM.

### Claim 20

In a method for synthesis of polypeptides in a cell-free in vitro reaction, the improvement comprising:
performing said protein synthesis in a reaction mixture comprising exogensous initiation factors at a concentration of at least about 1 nM, and plasmid DNA at a concentration of not more than about 2.5 nM.
